InMed Pharmaceuticals Presents Preclinical INM-901 Alzheimer’s Data at AAIC 2025

InMed Pharmaceuticals announced new preclinical data from its INM-901 program at the 2025 Alzheimer’s Association International Conference (AAIC), demonstrating promising multi-modal therapeutic effects in an advanced 5xFAD mouse model of Alzheimer’s disease. The data showed that long-term INM-901 treatment led to improvements in cognitive function, anxiety-related behavior, and sensory responsiveness, along with significant reductions in inflammatory biomarkers such as IFN-γ, TNF-α, and IL-1β, suggesting a dose-dependent effect on neuroinflammation. Additionally, gene expression related to inflammation, the endocannabinoid system, synaptic dysfunction, oxidative stress, and apoptosis showed trends toward normalization following treatment. These findings support INM-901’s potential to mitigate Alzheimer’s pathology through multiple mechanisms including reducing neuroinflammation and promoting neuronal regeneration. Despite these promising results, InMed's stock performance is challenged by financial and valuation concerns, with analysts rating it as underperform. The company continues to focus on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer’s disease.